Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRYSTAL-4 first-line adagrasib plus pembrolizumab and chemotherapy in KRAS G12C-mutant nonsquamous NSCLC
MOH_2024-11-21_013746Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Adagrasib + pembrolizumab + chemotherapy with Placebo + pembrolizumab + chemotherapy (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Feb 2025; status: recruiting.
02
Drugs
adagrasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2024-11-21_013746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-11-21_013746.